Innovations and Systems Approaches to Medication Safety in Pharmacy Practice

A special issue of Pharmacy (ISSN 2226-4787). This special issue belongs to the section "Pharmacy Practice and Practice-Based Research".

Deadline for manuscript submissions: 15 July 2026 | Viewed by 1468

Special Issue Editors


E-Mail Website
Guest Editor
College of Pharmacy, University of North Texas Health, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
Interests: medication safety; health outcomes research; pharmacy practice; interprofessional collaboration; patient safety; managed care pharmacy; artificial intelligence in healthcare

E-Mail Website
Guest Editor
Department of Pharmaceutical Economics and Policy, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, 9401 Jeronimo Road, Irvine, CA 92618-1908, USA
Interests: pharmaceutical economics; health policy; medication adherence; health services research; managed care pharmacy; value-based care; patient-centered outcomes

Special Issue Information

Dear Colleagues,

This Special Issue focuses on advancing medication safety through contemporary, systems-oriented approaches in diverse healthcare settings. Its scope encompasses the entire medication use process, spanning multidisciplinary teams, digital health tools, patient engagement, and high-risk medication management. The purpose is to consolidate evidence and present innovative, practical strategies that healthcare teams can implement to mitigate medication-related risks and build more resilient, patient-centered care systems.

By synthesizing insights across these interconnected domains, the issue demonstrates how technological integration, team-based care, and patient-centered initiatives collectively contribute to building more resilient and safer medication use systems for the future.

Dr. Annesha White
Prof. Dr. Marc Fleming
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medication safety
  • systems-based approaches
  • multidisciplinary team
  • interprofessional collaboration
  • digital health tools
  • patient engagement
  • medication management
  • chronic disease management
  • resilient healthcare systems

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1179 KB  
Article
Effectiveness of Gabapentinoids in Neuropathic Pain: A Single-Center Retrospective Study at a Specialized Institution in Mexico
by Carlos Eduardo Estrada-De La Rosa, Felipe Alexis Avalos-Salgado, Nancy Evelyn Navarro-Ruiz, Erika Fabiola López-Villalobos, Roberto de Jesús Sandoval-Muñiz, Monserratt Abud-González, María Luisa Muñoz-Almaguer and Raymundo Escutia-Gutiérrez
Pharmacy 2026, 14(2), 55; https://doi.org/10.3390/pharmacy14020055 - 29 Mar 2026
Viewed by 880
Abstract
Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited. This study aimed to evaluate the effectiveness and safety profile of gabapentinoid therapy in patients managed within a specialized pain [...] Read more.
Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited. This study aimed to evaluate the effectiveness and safety profile of gabapentinoid therapy in patients managed within a specialized pain relief institution. Methods: A retrospective cohort study (n = 109) was conducted (January 2024 to December 2024). Effectiveness was assessed via DN4 and VAS over one year. Time to improvement was analyzed using Kaplan–Meier curves. Results: The cohort (mean age 66.2 ± 15.3 years) presented 100% comorbidity and polypharmacy (66.1% opioids; 67.9% antidepressants). Although all patients showed improvement, only 35.8% achieved “maximal improvement.” Pregabalin demonstrated faster VAS reduction than gabapentin (p = 0.029), though long-term success was comparable (p = 0.30). Significantly, 100% of patients reported at least one adverse drug event (ADE), primarily somnolence (66.1%), though no serious ADEs occurred. Lower baseline pain scores were significant predictors of therapeutic success. Conclusions: Gabapentinoids are effective for long-term NP management; however, their use is consistently associated with non-serious ADEs. In specialized settings characterized by extensive CNS-active polypharmacy, proactive pharmacovigilance and multidisciplinary oversight are essential to balance analgesic effectiveness with medication safety. Full article
Show Figures

Graphical abstract

Back to TopTop